Go back

NHS innovative drugs fund risks fostering ‘weak evidence’

Fund aims to deliver “most promising medicines” but may disincentivise collection of evidence, study finds

A fund set up by the UK government to speed up access to new treatments risks incentivising the development of expensive drugs with weak evidence of clinical benefit, a new study has found.

In June, the government launched the £340 million Innovative Medicines Fund (IMF) for pharmaceutical companies to purchase the “most promising medicines” and fast-track them to patients before a final decision from the National Institute for Health and Care Excellence, which decides whether a drug or treatment should be made available through the NHS.

This article is only available to Research Professional News subscribers or Pivot-RP users.

If you are a Research Professional News subscriber you can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.